Posts

Strong VYVGART quarter tempered by another DM trial

on
argenx reported third-quarter 2026 VYVGART product sales of about $1.7 billion, up 54% year over year and 13% from the prior quarter. The main setback was dermatomyositis (DM): although the Phase 3 ALKIVIA study showed an encouraging treatment signal, it missed its primary endpoint. The FDA wants additional confirmatory evidence, so argenx plans another registrational trial before pursuing a DM filing. The update modestly weighed on investor sentiment, alongside concerns about operating expenses and profit. The company says it plans to submit for VYVGART Hytrulo in immune-mediated necrotizing myopathy (IMNM) by year-end 2026. Sources: argenx Reports Third Quarter 2026 Financial Results and ... Argenx confirmatory trial update for Vyvgart puts small dent ... Newsroom argenx.com · news · 2026argenx Reports Half Year 2026 Financial Results and Provides ... Argenx Wavers On A Surprise Requirement For Its Flagship Drug argenx (ARGX) Q3 2026 Earnings Call Transcript Spo...

Merck and Moderna release melanoma vaccine Phase 3 results early after leak

on

Roche reports 43.1% reduction in proteinuria in Phase 3 kidney-disease trial

on

Treasury proposal targets biotech investment but largely spares conventional China licensing deals

on

Gilead to acquire PepStar’s oral IL-23R program for $1.275 billion upfront

on

Bristol Myers faces renewed CAR-T safety questions after trial death

on

Roche licenses Zymeworks’ early-stage trispecific cancer drug

on

AbbVie’s lutikizumab meets Phase 3 goal, but efficacy falls short of expectations

on

Alnylam reports promising early knockdown data for Huntington’s drug

on

Tango’s pancreatic cancer combo shows 82% response rate

on

Pusan National University team develops AI tool to map RNA binding sites

on

Menarini licenses Georgiamune’s preclinical cancer drug in deal worth up to $1.1B

on

AbbVie’s lutikizumab meets Phase 3 goal in painful skin disease

on